請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/56280完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 黃慶璨(Ching-Tsan Huang) | |
| dc.contributor.author | Wan-Ling Hsieh | en |
| dc.contributor.author | 謝宛伶 | zh_TW |
| dc.date.accessioned | 2021-06-16T05:21:42Z | - |
| dc.date.available | 2019-08-22 | |
| dc.date.copyright | 2014-08-22 | |
| dc.date.issued | 2014 | |
| dc.date.submitted | 2014-08-15 | |
| dc.identifier.citation | 1. 許瑞祥 (1988) 靈芝的奧秘. 正義.
2. PA K (1881) Enumeratio boletinearum et polyporearum fennicarum systemate nove dispositarum. Review of mycologique 3:16-19. 3. 許瑞祥 (1993) 靈芝概論. 萬年. 4. Sliva D (2003) Ganoderma lucidum (Reishi) in cancer treatment. Integrative cancer therapies 2(4):358-364. 5. Yue QX, et al. (2010) Effects of triterpenes from Ganoderma lucidum on protein expression profile of HeLa cells. Phytomedicine : international journal of phytotherapy and phytopharmacology 17(8-9):606-613. 6. Gao Y, Deng XG, Sun QN, & Zhong ZQ (2010) Ganoderma spore lipid inhibits N-methyl-N-nitrosourea-induced retinal photoreceptor apoptosis in vivo. Experimental eye research 90(3):397-404. 7. Liang C, et al. (2012) Recombinant Lz-8 from Ganoderma lucidum induces endoplasmic reticulum stress-mediated autophagic cell death in SGC-7901 human gastric cancer cells. Oncology reports 27(4):1079-1089. 8. Min BS, Nakamura N, Miyashiro H, Bae KW, & Hattori M (1998) Triterpenes from the spores of Ganoderma lucidum and their inhibitory activity against HIV-1 protease. Chemical & pharmaceutical bulletin 46(10):1607-1612. 9. Sanodiya BS, Thakur GS, Baghel RK, Prasad GB, & Bisen PS (2009) Ganoderma lucidum: a potent pharmacological macrofungus. Current pharmaceutical biotechnology 10(8):717-742. 10. da Silva Coelho J, et al. (2010) Comparative removal of bentazon by Ganoderma lucidum in liquid and solid state cultures. Current microbiology 60(5):350-355. 11. Papinutti L (2010) Effects of nutrients, pH and water potential on exopolysaccharides production by a fungal strain belonging to Ganoderma lucidum complex. Bioresource technology 101(6):1941-1946. 12. Xu JW, Zhao W, Xu YN, & Zhong JJ (2012) Isolation and analysis of differentially expressed genes during asexual sporulation in liquid static culture of Ganoderma lucidum by suppression subtractive hybridization. Molecular biology reports 39(4):3603-3610. 13. Boh B, Berovic M, Zhang J, & Zhi-Bin L (2007) Ganoderma lucidum and its pharmaceutically active compounds. Biotechnology annual review 13:265-301. 14. Sliva D (2004) Cellular and physiological effects of Ganoderma lucidum (Reishi). Mini reviews in medicinal chemistry 4(8):873-879. 15. Gao Y, Zhou S, Wen J, Huang M, & Xu A (2002) Mechanism of the antiulcerogenic effect of Ganoderma lucidum polysaccharides on indomethacin-induced lesions in the rat. Life sciences 72(6):731-745. 16. Meng J, et al. (2011) Analysis of maturation of murine dendritic cells (DCs) induced by purified Ganoderma lucidum polysaccharides (GLPs). International journal of biological macromolecules 49(4):693-699. 17. Ko HH, Hung CF, Wang JP, & Lin CN (2008) Antiinflammatory triterpenoids and steroids from Ganoderma lucidum and G. tsugae. Phytochemistry 69(1):234-239. 18. Yuen JW, Gohel MD, & Ng CF (2011) The differential immunological activities of Ganoderma lucidum on human pre-cancerous uroepithelial cells. Journal of ethnopharmacology 135(3):711-718. 19. Wang JL, Gu T, & Zhong JJ (2012) Enhanced recovery of antitumor ganoderic acid T from Ganoderma lucidum mycelia by novel chemical conversion strategy. Biotechnology and bioengineering 109(3):754-762. 20. Kino K, et al. (1989) Isolation and characterization of a new immunomodulatory protein, ling zhi-8 (LZ-8), from Ganoderma lucidium. The Journal of biological chemistry 264(1):472-478. 21. Ko JL, Lin SJ, Hsu CI, Kao CL, & Lin JY (1997) Molecular cloning and expression of a fungal immunomodulatory protein, FIP-fve, from Flammulina velutipes. Journal of the Formosan Medical Association = Taiwan yi zhi 96(7):517-524. 22. 湯曉君 (2000) 金針菇免疫調節功能蛋白FIP-fve調控干擾素γ之研究. 私立中山醫學大學毒理學研究所碩士論文. 23. Hsu HC, Hsu CI, Lin RH, Kao CL, & Lin JY (1997) Fip-vvo, a new fungal immunomodulatory protein isolated from Volvariella volvacea. The Biochemical journal 323 ( Pt 2):557-565. 24. 張文馨 (2004) 真菌類免疫調節蛋白質FIP-vvo作用機制之研究. 國立台灣大學醫學院生物化學暨分子生物學研究所碩士論文. 25. 林采蔆 (2005) 靈芝屬免疫調節蛋白GMI與GFO-1基因之選殖與Pichia pasotris之異源表現. 國立臺灣大學微生物與生化學研究所碩士論文. 26. 賴明毅 (2010) 以嗜甲醇酵母菌表現靈芝屬免疫調節蛋白質LZ-8、GMI和GFO-1並探討其免疫調節功能. 國立台灣大學微生物與生化學研究所碩士論文. 27. 張慧欣 (2008) 茯苓免疫調節蛋白活化小鼠腹腔巨噬細胞之訊息路徑及促進T細胞活化與第一型T輔助細胞免疫反應. 國立臺灣大學園藝學研究所碩士論文. 28. 張慧欣 (2004) 茯苓免疫調節蛋白的純化與生理活性之探討. 國立台灣大學園藝學研究所碩士論文. 29. 曹巧吟 (2002) 樟芝中免疫調節蛋白的純化與其生理活性之探討. 國立台灣大學園藝學研究所碩士論文. 30. 錢家樂 (2004) 樟芝免疫調節蛋白基因選殖及表現之研究. 國立台灣大學園藝學研究所碩士論文. 31. Haak-Frendscho M, Kino K, Sone T, & Jardieu P (1993) Ling Zhi-8: a novel T cell mitogen induces cytokine production and upregulation of ICAM-1 expression. Cellular immunology 150(1):101-113. 32. Kino K, et al. (1991) Immunomodulator, LZ-8, prevents antibody production in mice. International journal of immunopharmacology 13(8):1109-1115. 33. Moradali MF, Mostafavi H, Ghods S, & Hedjaroude GA (2007) Immunomodulating and anticancer agents in the realm of macromycetes fungi (macrofungi). International immunopharmacology 7(6):701-724. 34. Tanaka S, et al. (1989) Complete amino acid sequence of an immunomodulatory protein, ling zhi-8 (LZ-8). An immunomodulator from a fungus, Ganoderma lucidium, having similarity to immunoglobulin variable regions. The Journal of biological chemistry 264(28):16372-16377. 35. Huang L, et al. (2009) Crystal structure of LZ-8 from the medicinal fungus Ganoderma lucidium. Proteins 75(2):524-527. 36. Kino K, et al. (1990) An immunomodulating protein, Ling Zhi-8 (LZ-8) prevents insulitis in non-obese diabetic mice. Diabetologia 33(12):713-718. 37. van der Hem LG, et al. (1995) Ling Zhi-8: studies of a new immunomodulating agent. Transplantation 60(5):438-443. 38. Hsu HY, et al. (2008) Reishi immuno-modulation protein induces interleukin-2 expression via protein kinase-dependent signaling pathways within human T cells. Journal of cellular physiology 215(1):15-26. 39. Lin YL, et al. (2009) An immunomodulatory protein, Ling Zhi-8, induced activation and maturation of human monocyte-derived dendritic cells by the NF-kappaB and MAPK pathways. Journal of leukocyte biology 86(4):877-889. 40. Wu CT, et al. (2011) Ling Zhi-8 mediates p53-dependent growth arrest of lung cancer cells proliferation via the ribosomal protein S7-MDM2-p53 pathway. Carcinogenesis 32(12):1890-1896. 41. Lin WH, Hung CH, Hsu CI, & Lin JY (1997) Dimerization of the N-terminal amphipathic alpha-helix domain of the fungal immunomodulatory protein from Ganoderma tsugae (Fip-gts) defined by a yeast two-hybrid system and site-directed mutagenesis. The Journal of biological chemistry 272(32):20044-20048. 42. 黃玉儒 (2003) 靈芝免疫調節蛋白的作用機制及其減緩塵蟎致敏之應用. 私立中山醫學大學毒理學研究所碩士論文. 43. Liao CH, et al. (2008) Induction of premature senescence in human lung cancer by fungal immunomodulatory protein from Ganoderma tsugae. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 46(5):1851-1859. 44. Liao CH, et al. (2007) Nuclear translocation of telomerase reverse transcriptase and calcium signaling in repression of telomerase activity in human lung cancer cells by fungal immunomodulatory protein from Ganoderma tsugae. Biochemical pharmacology 74(10):1541-1554. 45. Ko JL, Hsu CI, Lin RH, Kao CL, & Lin JY (1995) A new fungal immunomodulatory protein, FIP-fve isolated from the edible mushroom, Flammulina velutipes and its complete amino acid sequence. European journal of biochemistry / FEBS 228(2):244-249. 46. Paaventhan P, et al. (2003) A 1.7A structure of Fve, a member of the new fungal immunomodulatory protein family. Journal of molecular biology 332(2):461-470. 47. Ding Y, et al. (2009) Coadministration of the fungal immunomodulatory protein FIP-Fve and a tumour-associated antigen enhanced antitumour immunity. Immunology 128(1 Suppl):e881-894. 48. Hsieh CW, et al. (2007) Eosinophil apoptosis induced by fungal immunomodulatory peptide-fve via reducing IL-5alpha receptor. Journal of the Formosan Medical Association = Taiwan yi zhi 106(1):36-43. 49. Wang PH, et al. (2004) Fungal immunomodulatory protein from Flammulina velutipes induces interferon-gamma production through p38 mitogen-activated protein kinase signaling pathway. Journal of agricultural and food chemistry 52(9):2721-2725. 50. Chang HH, Hsieh KY, Yeh CH, Tu YP, & Sheu F (2010) Oral administration of an Enoki mushroom protein FVE activates innate and adaptive immunity and induces anti-tumor activity against murine hepatocellular carcinoma. International immunopharmacology 10(2):239-246. 51. Ou CC, et al. (2009) FIP-fve stimulates interferon-gamma production via modulation of calcium release and PKC-alpha activation. Journal of agricultural and food chemistry 57(22):11008-11013. 52. Liu YH, Kao MC, Lai YL, & Tsai JJ (2003) Efficacy of local nasal immunotherapy for Dp2-induced airway inflammation in mice: Using Dp2 peptide and fungal immunomodulatory peptide. The Journal of allergy and clinical immunology 112(2):301-310. 53. Wu CC, Liao EC, Lee MF, & Tsai JJ (2009) Augmentation of regulatory T cells in allergic individuals by recombinant Der f 2 peptide with fungal immunomodulatory peptide fve. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 102(3):216-222. 54. 林采蔆 (2005) 靈芝屬免疫調節蛋白GMI與GFO-1基因之選殖與Pichia pasotris之異源表現. 國立台灣大學微生物與生化學研究所碩士論文. 55. 吳明玥 (2008) 利用熱休克蛋白質5'端非轉譯片段調控免疫調節蛋白質GMI於米麴菌表達系統之產量. 國立台灣大學微生物與生化學研究所碩士論文. 56. 蔣友邦 (2012) 小孢子靈芝免疫調節蛋白質GMI雙體化對其免疫調節功能之影響. 國立台灣大學生化科技學系碩士論文. 57. Ching-Hsiung Lin G-TS, Yu-Wen Lin, Chin-Shui Yeh, Yu-Hsin Huang, Yen-Chein Lai, Jan-Gowth Chang, Jiunn-Liang Ko (2010) A new immunomodulatory protein from Ganoderma microsporum inhibits epidermal growth factor mediated migration and invasion in A549 lung cancer cells. Process Biochemistry 45:1537-1542. 58. Lin CH, et al. (2010) GMI, a Ganoderma immunomodulatory protein, down-regulates tumor necrosis factor alpha-induced expression of matrix metalloproteinase 9 via NF-kappaB pathway in human alveolar epithelial A549 cells. Journal of agricultural and food chemistry 58(22):12014-12021. 59. Hsin IL, et al. (2011) GMI, an immunomodulatory protein from Ganoderma microsporum, induces autophagy in non-small cell lung cancer cells. Autophagy 7(8):873-882. 60. Hsin IL, et al. (2012) Inhibition of lysosome degradation on autophagosome formation and responses to GMI, an immunomodulatory protein from Ganoderma microsporum. British journal of pharmacology 167(6):1287-1300. 61. 林千椀 (2008) 利用分子演化增加小孢子靈芝選殖之免疫調節蛋白質GMI的免疫活性. 國立台灣大學微生物與生化學研究所碩士論文. 62. 翁瑞芸 (2011) 小孢子靈芝免疫調節蛋白質GMI之功能與結構分析. 國立台灣大學生化科技學系碩士論文. 63. Sette A, et al. (2009) Definition of epitopes and antigens recognized by vaccinia specific immune responses: their conservation in variola virus sequences, and use as a model system to study complex pathogens. Vaccine 27 Suppl 6:G21-26. 64. DH D (2008) Immune System. Encyclopedia of Life Sciences-Immunology:1-10. 65. Kono H & Rock KL (2008) How dying cells alert the immune system to danger. Nature reviews. Immunology 8(4):279-289. 66. SK D (Cytokines and the Immune System Cytokine Reference.95-97. 67. Hanahan D & Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57-70. 68. Raoul JL (2008) Natural history of hepatocellular carcinoma and current treatment options. Seminars in nuclear medicine 38(2):S13-18. 69. Fodde R & Smits R (2002) Cancer biology. A matter of dosage. Science 298(5594):761-763. 70. Bruno BJ, Miller GD, & Lim CS (2013) Basics and recent advances in peptide and protein drug delivery. Therapeutic delivery 4(11):1443-1467. 71. Jain A, et al. (2013) Peptide and protein delivery using new drug delivery systems. Critical reviews in therapeutic drug carrier systems 30(4):293-329. 72. Li H, Aneja R, & Chaiken I (2013) Click chemistry in peptide-based drug design. Molecules 18(8):9797-9817. 73. Craik DJ, Fairlie DP, Liras S, & Price D (2013) The future of peptide-based drugs. Chemical biology & drug design 81(1):136-147. 74. Kangueane P (2005) Welcome to 'Bioinformation' a data journal. Bioinformation 1(1):1. 75. Milosavljevic A (2000) The economic value of bioinformation. Bioinformatics 16(7):571-572. 76. Rein G (2004) Bioinformation within the biofield: beyond bioelectromagnetics. Journal of alternative and complementary medicine 10(1):59-68. 77. Perrizo W (2007) The role of data mining in turning bio-data into Bioinformation. Bioinformation 1(9):351-355. 78. Wu OP, Seow KT, Wong L, Chung SY, & Subbiah S (1998) From sequence to structure to literature: the protocol approach to bioinformation. Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing:747-758. 79. Nevalainen KM, Te'o VS, & Bergquist PL (2005) Heterologous protein expression in filamentous fungi. Trends in biotechnology 23(9):468-474. 80. Fish NM & Hoare M (1988) Recovery of protein inclusion bodies. Biochemical Society transactions 16(2):102-104. 81. Cereghino JL & Cregg JM (2000) Heterologous protein expression in the methylotrophic yeast Pichia pastoris. FEMS microbiology reviews 24(1):45-66. 82. Bretthauer RK & Castellino FJ (1999) Glycosylation of Pichia pastoris-derived proteins. Biotechnology and applied biochemistry 30 ( Pt 3):193-200. 83. Smith RA, Duncan MJ, & Moir DT (1985) Heterologous protein secretion from yeast. Science 229(4719):1219-1224. 84. 何文旭 (2006) 以米麴菌表達由小孢子靈芝選殖之免疫調節蛋白質GMI. 國立台灣大學微生物與生化學研究所碩士論文. 85. Rock KL, Rothstein L, Gamble S, & Fleischacker C (1993) Characterization of antigen-presenting cells that present exogenous antigens in association with class I MHC molecules. Journal of immunology 150(2):438-446. 86. Bernhard H, et al. (2000) Dendritic cells lose ability to present protein antigen after stimulating antigen-specific T cell responses, despite upregulation of MHC class II expression. Immunobiology 201(5):568-582. 87. Eisenberg D, Weiss RM, & Terwilliger TC (1982) The helical hydrophobic moment: a measure of the amphiphilicity of a helix. Nature 299(5881):371-374. 88. Manning G, Whyte DB, Martinez R, Hunter T, & Sudarsanam S (2002) The protein kinase complement of the human genome. Science 298(5600):1912-1934. 89. Sheng WY & Huang L (2011) Cancer immunotherapy and nanomedicine. Pharmaceutical research 28(2):200-214. 90. Danciu TE & Whitman M (2010) Oxidative stress drives disulfide bond formation between basic helix-loop-helix transcription factors. Journal of cellular biochemistry 109(2):417-424. 91. Mutter M, Maser F, Altmann KH, Toniolo C, & Bonora GM (1985) Sequence-dependence of secondary structure formation: conformational studies of host-guest peptides in alpha-helix and beta-structure supporting media. Biopolymers 24(6):1057-1074. 92. Basharov MA, Vol'kenshtein MV, Golovanov IB, Nauchitel VV, & Sobolev VM (1987) [Stability of the alpha-helix structure of oligopeptides]. Molekuliarnaia biologiia 21(3):743-749. 93. Kiyoi H, Naoe T, Horibe K, & Ohno R (1992) Characterization of the immunoglobulin heavy chain complementarity determining region (CDR)-III sequences from human B cell precursor acute lymphoblastic leukemia cells. The Journal of clinical investigation 89(3):739-746. 94. Kupcsik L (2011) Estimation of cell number based on metabolic activity: the MTT reduction assay. Methods in molecular biology 740:13-19. 95. van Meerloo J, Kaspers GJ, & Cloos J (2011) Cell sensitivity assays: the MTT assay. Methods in molecular biology 731:237-245. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/56280 | - |
| dc.description.abstract | 自小孢子靈芝 (Ganoderma microsporum) 分離出之真菌免疫調節蛋白質 (Fungal immunomodulatory protein) GMI 已證實能藉由與細胞膜表面受器作用，活化下游訊息傳遞路徑，進而具有調節細胞免疫反應 (Cell immune) 或抗腫瘤 (Anti-tumor) 等功效。本研究探討位於 GMI 部分片段 (Partial fragments) 之生理活性。藉由二級結構的比對及生物資訊軟體的分析，篩選出一個 α-helix 片段及三個 β-sheet 短胜肽 (Peptides) 片段進行化學合成，生產高純度及高產量之短胜肽。據細胞免疫活性測試結果顯示野生型蛋白質 GMI 及突變型蛋白質 GMI-L6C 皆能有效促進人類淋巴癌 T 細胞株 Jurkat 分泌 IL-2，而 α-helix 短胜肽 (GMIαL6C) 及三個 β-sheet 短胜肽 (GMIβ1531、GMIβ4567 及 GMIβ85103) 則無法促使 Jurkat 分泌 IL-2。在抗腫瘤活性測試中，GMI 及 GMI-L6C 皆能降低人類肺癌細胞株 A549 的存活率及移動能力，雙體的 α-helix 短胜肽 (GMIαL6C) 具抑制 A549 存活率及移動效果，而三個 β-sheet 短胜肽 (GMIβ1531、GMIβ4567 及 GMIβ85103) 則不具影響 A549 存活率及移動的能力。藉由細胞免疫及抗腫瘤試驗結果，GMI-L6C 相較於 GMI 可提升蛋白質免疫調節及抗腫瘤能力，證實穩定雙體構形與其生理活性的必要性；α-helix 短胜肽具抗腫瘤效果，顯示 α-helix 於 GMI 抗腫瘤活性的重要性；而三個 β-sheet 短胜肽則不具生理活性。 | zh_TW |
| dc.description.abstract | GMI, a fungal immunomodulatory protein (FIP) isolated from Ganoderma microsporum had been reported that it could interact with cell surface receptors and trigger downstream signal transduction. According to these evidences, FIPs exhibit potent immunomodulation and anti-tumor effect. In this study, we investigated the partial fragments within GMI and analyzed their bioactivities. By analyzing the secondary structure alignment and bioinformatics data, selected one α-helix and three β-sheet amino acid sequences. In order to get high quality and output target peptides, these peptides were produced by chemical synthesis. In terms of cell immune assay, wild type protein GMI and mutative protein GMI-L6C could enhance Jurkat T cells to secret IL-2 but α-helix-peptide and three β-sheet-peptides could not. By analyzing the results of anti-tumor tests, GMI and GMI-L6C could inhibit A549 viability and migration. Interestingly, α-helix-peptide could affect A549 viability and migration. However, three β-sheet-peptides could not inhibit A549 neither viability nor migration. Based on cell immune and anti-tumor assays, GMI-L6C exhibited better immunomodulatory and anti-tumor ability. It’s indicated dimerization is important to its bioactivity. By α-helix-peptide exhibiting anti-tumor activity, it suggested the importance of α-helix in anti-tumor activity of GMI. On the contrary, β-sheet-peptides didn’t have immunomodulatory and anti-tumor activity. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-16T05:21:42Z (GMT). No. of bitstreams: 1 ntu-103-R01b22035-1.pdf: 7678862 bytes, checksum: 0b10128da906be0382391d8c96176bfa (MD5) Previous issue date: 2014 | en |
| dc.description.tableofcontents | 摘要 I
Abstract II 目錄 III 圖目錄 VI 表目錄 VIII 第一章 前言 1 一、靈芝 1 二、真菌免疫調節蛋白質 2 1. LZ-8 3 2. FIP-gts 3 3. FIP-fve 4 4. FIP-vvo 5 5. FIP-gja 5 6. GMI 5 7. GFO-1、GFO-2 6 三、免疫系統 7 四、癌症治療 8 五、小胜肽藥物 9 六、生物資訊運用 10 七、異源表現系統 11 1. 原核表達系統 11 2. 真核表達系統 11 八、研究動機與目的 13 第二章 材料與方法 30 一、細菌與真菌實驗 30 1. 培養基與藥品 30 2. 菌株與培養條件 31 3. 質體與轉形株 32 二、 蛋白質表現及分析 34 1. P. pastoris 異源蛋白質表現 34 2. P. pastoris 異源蛋白質濃縮與純化 34 3. 蛋白質定量 35 4. 蛋白質聚丙烯醯胺膠體電泳 (SDS-PAGE) 36 5. 西方墨點法 (Western blot) 37 三、生物資訊軟體分析 38 四、 胜肽合成 39 五、奈米微粒分析儀 40 六、細胞實驗 41 1. 細胞培養 41 2. 細胞免疫活性測試 43 3. 抗腫瘤活性測試 45 七、統計分析 46 第三章 實驗結果 47 一、重組蛋白質表現與純化 47 1. 以搖瓶培養生產重組蛋白質 47 2. 蛋白質濃縮與純化 47 3. 蛋白質電泳分析 47 4. 西方墨點法確認蛋白質表現 48 二、篩選目標胜肽合成 51 三、蛋白質及胜肽粒徑大小分析 59 四、細胞免疫活性測試 63 1. 蛋白質及胜肽樣品刺激人類淋巴癌 T 細胞株 Jurkat 63 2. 蛋白質樣品 IL-2 ELISA 結果分析 63 3. 胜肽樣品 IL-2 ELISA 結果分析 63 五、抗腫瘤活性測試 68 1. 分析蛋白質及胜肽樣品抑制人類肺癌細胞株 A549 存活能力 68 2. 分析蛋白質及胜肽樣品抑制人類肺癌細胞株 A549 移動能力 69 第四章 討論 84 一、篩選目標胜肽合成 84 1. α-helix 序列篩選 84 2. β-sheet 序列篩選 85 二、蛋白質及胜肽粒徑大小分析 86 1. 蛋白質樣品單/雙體分析 86 2. 胜肽樣品單/雙體分析 87 三、細胞免疫活性測試 88 1. 蛋白質樣品刺激人類淋巴癌 T 細胞株 Jurkat 88 2. 胜肽樣品刺激人類淋巴癌 T 細胞株 Jurkat 88 四、抗腫瘤活性測試 90 1. 人類肺癌細胞株 A549 存活率分析 90 2. 人類肺癌細胞株 A549 移動能力分析 91 第五章 結論 93 第六章 未來展望 95 第七章 參考文獻 97 | |
| dc.language.iso | zh-TW | |
| dc.subject | 細胞免疫 | zh_TW |
| dc.subject | GMI | zh_TW |
| dc.subject | 真菌免疫調節蛋白質 | zh_TW |
| dc.subject | 胜? | zh_TW |
| dc.subject | α-helix | zh_TW |
| dc.subject | β-sheet | zh_TW |
| dc.subject | 抗腫瘤 | zh_TW |
| dc.subject | GMI | en |
| dc.subject | anti-tumor | en |
| dc.subject | cell immune | en |
| dc.subject | β-sheet | en |
| dc.subject | α-helix | en |
| dc.subject | fungal immunomodulatory proteins (FIPs) | en |
| dc.subject | peptide | en |
| dc.title | 小孢子靈芝免疫調節蛋白質 GMI 部分片段之生理活性分析 | zh_TW |
| dc.title | Bioactivity analysis of partial fragments within GMI, an immunomodulatory protein from Ganoderma microsporum | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 102-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 許瑞祥(Ruey-Shyang Hseu),陳進庭(Chin-Tin Chen),楊?伸(Chii-Shen Yang) | |
| dc.subject.keyword | 真菌免疫調節蛋白質,GMI,胜?,α-helix,β-sheet,細胞免疫,抗腫瘤, | zh_TW |
| dc.subject.keyword | fungal immunomodulatory proteins (FIPs),GMI,peptide,α-helix,β-sheet,cell immune,anti-tumor, | en |
| dc.relation.page | 104 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2014-08-15 | |
| dc.contributor.author-college | 生命科學院 | zh_TW |
| dc.contributor.author-dept | 生化科技學系 | zh_TW |
| 顯示於系所單位： | 生化科技學系 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-103-1.pdf 未授權公開取用 | 7.5 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。